1. Home
  2. NTLA vs GHLD Comparison

NTLA vs GHLD Comparison

Compare NTLA & GHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • GHLD
  • Stock Information
  • Founded
  • NTLA 2014
  • GHLD 1960
  • Country
  • NTLA United States
  • GHLD United States
  • Employees
  • NTLA N/A
  • GHLD N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GHLD Finance: Consumer Services
  • Sector
  • NTLA Health Care
  • GHLD Finance
  • Exchange
  • NTLA Nasdaq
  • GHLD Nasdaq
  • Market Cap
  • NTLA 794.5M
  • GHLD 813.7M
  • IPO Year
  • NTLA 2016
  • GHLD 2020
  • Fundamental
  • Price
  • NTLA $9.20
  • GHLD $19.76
  • Analyst Decision
  • NTLA Buy
  • GHLD Hold
  • Analyst Count
  • NTLA 20
  • GHLD 6
  • Target Price
  • NTLA $36.60
  • GHLD $16.30
  • AVG Volume (30 Days)
  • NTLA 6.0M
  • GHLD 67.2K
  • Earning Date
  • NTLA 08-07-2025
  • GHLD 08-07-2025
  • Dividend Yield
  • NTLA N/A
  • GHLD 2.53%
  • EPS Growth
  • NTLA N/A
  • GHLD 63.18
  • EPS
  • NTLA N/A
  • GHLD 0.71
  • Revenue
  • NTLA $45,569,000.00
  • GHLD $1,131,796,000.00
  • Revenue This Year
  • NTLA N/A
  • GHLD $5.64
  • Revenue Next Year
  • NTLA N/A
  • GHLD $26.37
  • P/E Ratio
  • NTLA N/A
  • GHLD $27.80
  • Revenue Growth
  • NTLA N/A
  • GHLD 32.57
  • 52 Week Low
  • NTLA $5.90
  • GHLD $11.21
  • 52 Week High
  • NTLA $28.18
  • GHLD $20.15
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 57.28
  • GHLD 82.47
  • Support Level
  • NTLA $8.00
  • GHLD $14.69
  • Resistance Level
  • NTLA $10.52
  • GHLD $20.15
  • Average True Range (ATR)
  • NTLA 0.67
  • GHLD 0.63
  • MACD
  • NTLA 0.15
  • GHLD 0.54
  • Stochastic Oscillator
  • NTLA 63.35
  • GHLD 94.54

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About GHLD Guild Holdings Company

Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.

Share on Social Networks: